Hjem › Parkinsons sykdom › Washington
Kliniske studier for Parkinsons sykdom i Washington
15 studier for Parkinsons sykdom søker deltakere på steder i Washington.
Byer i Washington
Offisiell studietekst (engelsk)
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- EvergreenHealth, Kirkland
- Inland Northwest Research, Spokane
RekruttererFase 2
Alder 40 til 80 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06680830A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
- Site-007, Bellevue
- Site-019, Seattle
RekruttererFase 2/3
Alder 40 til 80 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06976268A Study of Buntanetap in Participants With PD
- Inland Northwest Research, Spokane
RekruttererFase 2/3
Alder 40 til 85 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT07284784Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
- Inland Northwest Research, Spokane
RekruttererFase 2
Alder 40 til 80 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT07005180Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
- Evergreen Health, Kirkland
- Virginia Mason Medical Center, Seattle
- University of Washington Medical Center, Seattle
- og 1 flere
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT02071134A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
- Vima Site #023, Kirkland
- Vima Site #015, Spokane
RekruttererFase 2
Alder 18 til 65 · Alle kjønn · Oppdatert 11. sep. 2026 · NCT07804615A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
- EvergreenHealth (Site #219), Kirkland
RekruttererFase 2
Alder 30 til 80 · Alle kjønn · Oppdatert 10. sep. 2026 · NCT07432958Parkinson's Foundation PD GENEration Genetic Registry
- Evergreen Health, Kirkland
- Inland Northwest Research, Spokane
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT04994015A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
- VA Puget Sound Health Care System, Seattle
RekruttererObservasjonsstudie
Alder 45 til 75 · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07330258A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
- EvergreenHealth - Research Department, Kirkland
RekruttererFase 3
Alder 45 til 75 · Alle kjønn · Oppdatert 4. aug. 2026 · NCT06944522PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
- Univ of Washington and VA Puget Sound Health Care System, Seattle
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 30 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT04477785Use of CereGate Therapy for Freezing of Gait in PD
- University of Washington, Seattle
Rekrutterer
Alder 21 til 80 · Alle kjønn · Oppdatert 28. mai 2026 · NCT05292794A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
- Evergreen Health Research, Kirkland
- Inland Northwest Research, Spokane
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 30 til 85 · Alle kjønn · Oppdatert 20. apr. 2026 · NCT06809400The Parkinson's Genetic Research Study
- VA Puget Sound Health Care System, Seattle
- University of Washington, Seattle
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 14. mai 2024 · NCT01558479Modifiable Variables in Parkinsonism (MVP)
- Bastyr University, Kenmore
RekruttererObservasjonsstudie
Alder 19 og eldre · Alle kjønn · Oppdatert 25. mar. 2022 · NCT02194816Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.